MedTrace Logo

A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors

NCT06322095 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-10-01

No results posted yet for this study

Summary

This study is aim to evaluate the preliminary efficacy of GH21 combined with previous target therapy or immunotherapy in patients with advanced solid tumors.

Conditions

  • Patients With Advanced Solid Tumor
  • Advanced Solid Tumor With Oncogenic Driver Mutations

Interventions

DRUG

PD-1

Previous PD-1

DRUG

MET inhibitor

Previous MET inhibitor

DRUG

ALK inhibitor

Previous ALK inhibitor

DRUG

BRAF Inhibito

Previous BRAF inhibitor

DRUG

EGFR Monoclonal antibody

Previous EGFR Monoclonal antibody

DRUG

GH21

Oral, 15mg BIW or 6mg QD

DRUG

MEK Inhibitor

Previous MEK Inhibitor

Sponsors & Collaborators

  • Suzhou Genhouse Bio Co., Ltd.

    lead OTHER

Principal Investigators

  • Ning Li, Doctorate · +86-10-87788495

  • Haidan Wang, Doctorate · +86-512-86861608

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-22
Primary Completion
2025-09-30
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06322095 on ClinicalTrials.gov